Revolution Medicines (RVMD) Stock Price, News & Analysis

Company Overview

Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers. The company is evaluating these and other candidates in clinical studies across several solid-tumor indications.

Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines conducts its drug-discovery and clinical-development activities primarily in the United States. The company is led by Mark A. Goldsmith, who serves as chairman and chief executive officer.

Key Stats

• Today's Range: $184.76 to $191.60
• 50-Day Range: $182.45 to $221.15
• 52-Week Range: $47.45 to $224.31
• Volume: 446,134 shs
• Average Volume: 2.86 million shs
• Market Capitalization: $40.79 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $234.76
• Consensus Rating: Moderate Buy

Revolution Medicines Stock Analysis - MarketRank™

Revolution Medicines scored higher than 60% of companies evaluated by MarketBeat, and ranked 368th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Revolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 21 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Revolution Medicines has a consensus price target of $234.76, representing about 23.6% upside from its current price of $189.87.

Amount of Analyst Coverage

Revolution Medicines has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Revolution Medicines are expected to grow in the coming year, from ($8.98) to ($6.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revolution Medicines is -21.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revolution Medicines is -21.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Revolution Medicines has a P/B Ratio of 22.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.02% of the float of Revolution Medicines has been sold short.

Short Interest Ratio / Days to Cover

Revolution Medicines has a short interest ratio ("days to cover") of 4.65.

Change versus previous month

Short interest in Revolution Medicines has recently increased by 23.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revolution Medicines does not currently pay a dividend.

Dividend Growth

Revolution Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.35

News Sentiment

Revolution Medicines has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Revolution Medicines this week, compared to 8 articles on an average week.

Search Interest

Only 14 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

MarketBeat Follows

20 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 82% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,422,765.00 in company stock.

Percentage Held by Insiders

7.60% of the stock of Revolution Medicines is held by insiders.

Percentage Held by Institutions

94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RVMD
• CIK: 1628171
• Web: www.revmed.com
• Phone: 650-481-6801
• Fax: N/A
• Employees: 883
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Revolution Medicines: $234.76
• High Price Target: $320.00
• Low Price Target: $80.00
• Potential Upside/Downside: +23.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.13 billion
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -88.20%
• Return on Assets: -57.85%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 11.38
• Quick Ratio: 11.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.44 per share
• Price / Book: 22.49

Miscellaneous

• Outstanding Shares: 214,336,000
• Free Float: 198,046,000
• Market Cap: $40.69 billion
• Optionable: Optionable
• Beta: 1.40